Plexium, Inc. is a leading targeted protein degradation (TPD) company based in San Diego, CA. They are at the forefront of rational design and discovery of monovalent protein degraders, utilizing their best-in-class TPD platform and proprietary high-throughput cell-based screening technology to push the boundaries of TPD and unlock limitless possibilities in drug-like protein degraders.
With a diverse pipeline of wholly-owned and partnered programs, Plexium is dedicated to delivering innovative TPD therapies in areas of high unmet medical need against difficult-to-drug targets. Their expansive platform enables the discovery of new molecular glues, monovalent direct degraders, and novel E3 ligases, propelling the field of Target Protein Degradation forward and reimagining the future of drug discovery.
Generated from the website